(EBS) Emergent Biosolutions - Overview

Sector: Healthcare | Industry: Drug Manufacturers - Specialty & Generic | Exchange: NYSE (USA) | Market Cap: 436m USD | Total Return: 41.2% in 12m

Vaccines, Opioid Antagonists, Therapeutics, Contract Manufacturing
Total Rating 43
Safety 82
Buy Signal -0.32
Drug Manufacturers - Specialty & Generic
Industry Rotation: -4.2
Market Cap: 436M
Avg Turnover: 6.53M
Risk 3d forecast
Volatility107%
VaR 5th Pctl14.1%
VaR vs Median-29.4%
Reward TTM
Sharpe Ratio0.76
Rel. Str. IBD54.2
Rel. Str. Peer Group33
Character TTM
Beta2.783
Beta Downside2.477
Hurst Exponent0.307
Drawdowns 3y
Max DD84.58%
CAGR/Max DD0.04
CAGR/Mean DD0.07
EPS (Earnings per Share) EPS (Earnings per Share) of EBS over the last years for every Quarter: "2021-03": 1.53, "2021-06": 0.33, "2021-09": -0.36, "2021-12": 4.5, "2022-03": 0.18, "2022-06": -0.86, "2022-09": -1.27, "2022-12": -0.31, "2023-03": -3.17, "2023-06": -1.06, "2023-09": -5.08, "2023-12": -0.77, "2024-03": 0.59, "2024-06": -2.32, "2024-09": 1.37, "2024-12": -0.5775, "2025-03": 0.71, "2025-06": 0.16, "2025-09": 1.06, "2025-12": -0.43, "2026-03": 0.21,
Last SUE: 0.45
Qual. Beats: 0
Revenue Revenue of EBS over the last years for every Quarter: 2021-03: 343, 2021-06: 397.5, 2021-09: 329, 2021-12: 723.2, 2022-03: 307.5, 2022-06: 239.9, 2022-09: 239.9, 2022-12: 330.7, 2023-03: 164.3, 2023-06: 337.9, 2023-09: 270.5, 2023-12: 276.6, 2024-03: 300.4, 2024-06: 254.7, 2024-09: 293.8, 2024-12: 194.7, 2025-03: 222.2, 2025-06: 140.9, 2025-09: 231.1, 2025-12: 148.7, 2026-03: 156.1,
Rev. CAGR: -16.33%
Rev. Trend: -86.9%
Last SUE: -0.08
Qual. Beats: 0

Warnings

Choppy

Tailwinds

No distinct edge detected

Description: EBS Emergent Biosolutions

Emergent BioSolutions Inc. (NYSE: EBS) is a life sciences company specializing in medical countermeasures (MCM) for public health threats, including chemical, biological, and opioid-related risks. The company operates across three primary segments: Commercial Products, MCM Products, and Services. Its portfolio includes vaccines and therapeutics for anthrax, smallpox, mpox, and Ebola, alongside NARCAN nasal spray for opioid overdose reversal.

The business model relies heavily on government procurement contracts, as many of its products are developed for national strategic stockpiles rather than traditional consumer markets. This sector is characterized by high barriers to entry due to stringent regulatory requirements and the specialized nature of biosafety manufacturing. In addition to product sales, the company leverages its infrastructure to provide contract development and manufacturing organization (CDMO) services to external pharmaceutical partners.

Investors can evaluate the specific valuation metrics and historical performance of this stock by visiting ValueRay.

Headquartered in Gaithersburg, Maryland, Emergent BioSolutions maintains a presence in the United States, Canada, and international markets. The company’s integrated approach combines internal product development with third-party manufacturing services to address both emergency preparedness and commercial healthcare needs.

Headlines to Watch Out For
  • Narcan nasal spray sales volume shifts toward over-the-counter retail market
  • Government procurement cycles for anthrax and smallpox medical countermeasures
  • Debt restructuring efforts and asset divestitures impact balance sheet stability
  • Contract development and manufacturing utilization rates influence gross margin recovery
  • Global public health emergencies drive demand for mpox and ebola therapeutics
Piotroski VR-10 (Strict) 5.0
Net Income: -8.60m TTM > 0 and > 6% of Revenue
FCF/TA: 0.10 > 0.02 and ΔFCF/TA 3.64 > 1.0
NWC/Revenue: 72.24% < 20% (prev 61.62%; Δ 10.61% < -1%)
CFO/TA 0.11 > 3% & CFO 148.0m > Net Income -8.60m
Net Debt (413.3m) to EBITDA (166.6m): 2.48 < 3
Current Ratio: 4.29 > 1.5 & < 3
Outstanding Shares: last quarter (56.5m) vs 12m ago -1.40% < -2%
Gross Margin: 44.44% > 18% (prev 0.36%; Δ 4.41k% > 0.5%)
Asset Turnover: 49.28% > 50% (prev 67.70%; Δ -18.41% > 0%)
Interest Coverage Ratio: 1.28 > 6 (EBITDA TTM 166.6m / Interest Expense TTM 55.6m)
Altman Z'' 2.19
A: 0.37 (Total Current Assets 637.6m - Total Current Liabilities 148.7m) / Total Assets 1.32b
B: -0.12 (Retained Earnings -153.0m / Total Assets 1.32b)
C: 0.05 (EBIT TTM 71.2m / Avg Total Assets 1.37b)
D: -0.20 (Book Value of Equity -159.8m / Total Liabilities 797.3m)
Altman-Z'' = 2.19 = BBB
Beneish M -3.62
DSRI: 0.85 (Receivables 121.6m/203.7m, Revenue 676.8m/965.4m)
GMI: 0.82 (GM 44.44% / 36.43%)
AQI: 1.05 (AQ_t 0.37 / AQ_t-1 0.35)
SGI: 0.70 (Revenue 676.8m / 965.4m)
TATA: -0.12 (NI -8.60m - CFO 148.0m) / TA 1.32b)
Beneish M = -3.62 (Cap -4..+1) = AAA
What is the price of EBS shares?

As of May 30, 2026, the stock is trading at USD 9.12 with a total of 1,157,048 shares traded.
Over the past week, the price has changed by +8.96%, over one month by +14.14%, over three months by +11.90% and over the past year by +41.18%.

Is EBS a buy, sell or hold?

Emergent Biosolutions has received a consensus analysts rating of 3.67. Therefore, it is recommended to hold EBS.

  • StrongBuy: 1
  • Buy: 1
  • Hold: 0
  • Sell: 1
  • StrongSell: 0

What are the forecasts/targets for the EBS price?
Analysts Target Price 12 31.6%
Emergent Biosolutions (EBS) - Fundamental Data Overview as of 28 May 2026
Market Cap USD = 436.0m (436.0m USD * 1.0 USD.USD)
P/E Forward = 2.0773
P/S = 0.696
P/B = 0.9005
P/EG = 0.3835
Revenue TTM = 676.8m USD
EBIT TTM = 71.2m USD
EBITDA TTM = 166.6m USD
Long Term Debt = 573.6m USD (from longTermDebt, last quarter)
 Short Term Debt = unknown (none)
 Debt = 573.6m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 413.3m USD (calculated: Debt 573.6m - CCE 160.3m)
Enterprise Value = 849.3m USD (436.0m + Debt 573.6m - CCE 160.3m)
Interest Coverage Ratio = 1.28 (Ebit TTM 71.2m / Interest Expense TTM 55.6m)
EV/FCF = 6.27x (Enterprise Value 849.3m / FCF TTM 135.4m)
FCF Yield = 15.94% (FCF TTM 135.4m / Enterprise Value 849.3m)
FCF Margin = 20.01% (FCF TTM 135.4m / Revenue TTM 676.8m)
Net Margin = -1.27% (Net Income TTM -8.60m / Revenue TTM 676.8m)
Gross Margin = 44.44% ((Revenue TTM 676.8m - Cost of Revenue TTM 376.0m) / Revenue TTM)
Gross Margin QoQ = 43.31% (prev 31.34%)
Tobins Q-Ratio = 0.64 (Enterprise Value 849.3m / Total Assets 1.32b)
Interest Expense / Debt = 9.69% (Interest Expense 55.6m / Debt 573.6m)
Taxrate = 49.25% (6.60m / 13.4m)
NOPAT = 36.1m (EBIT 71.2m * (1 - 49.25%))
Current Ratio = 4.29 (Total Current Assets 637.6m / Total Current Liabilities 148.7m)
Debt / Equity = 1.10 (Debt 573.6m / totalStockholderEquity, last quarter 523.1m)
Debt / EBITDA = 2.48 (Net Debt 413.3m / EBITDA 166.6m)
Debt / FCF = 3.05 (Net Debt 413.3m / FCF TTM 135.4m)
Total Stockholder Equity = 541.1m (last 4 quarters mean from totalStockholderEquity)
RoA = -0.63% (Net Income -8.60m / Total Assets 1.32b)
RoE = -1.24% (Net Income TTM -8.60m / Total Stockholder Equity 694.1m)
RoCE = 5.62% (EBIT 71.2m / Capital Employed (Equity 694.1m + L.T.Debt 573.6m))
RoIC = 3.08% (NOPAT 36.1m / Invested Capital 1.17b)
WACC = 9.60% (E(436.0m)/V(1.01b) * Re(15.77%) + D(573.6m)/V(1.01b) * Rd(9.69%) * (1-Tc(0.49)))
Discount Rate = 15.77% (= CAPM, Blume Beta Adj.) -> capped to 13.17%
Shares (quarterly) Correlation: 47.74 | Cagr: 3.85%
[DCF] Terminal Value 74.02% ; FCFF base≈119.0m ; Y1≈136.4m ; Y5≈200.8m
[DCF] Fair Price = 39.94 (EV 2.47b - Net Debt 413.3m = Equity 2.06b / Shares 51.6m; r=9.60% [WACC]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.45 | # QB: 0
Revenue Correlation: -86.91 | Revenue CAGR: -16.33% | SUE: -0.08 | # QB: 0
EPS current Quarter (2026-06-30): EPS=0.11 | Chg30d=+0.00% | Revisions=N/A | Analysts=1
EPS next Quarter (2026-09-30): EPS=0.35 | Chg30d=+40.00% | Revisions=+20% | Analysts=1
EPS current Year (2026-12-31): EPS=0.95 | Chg30d=+82.69% | Revisions=+20% | GrowthEPS=-37.9% | GrowthRev=-1.3%
EPS next Year (2027-12-31): EPS=0.91 | Chg30d=+295.65% | Revisions=+20% | GrowthEPS=+398.4% | GrowthRev=+21.7%